Top

News & Events

Client News

Client News

Dimerix and Proteomics Partner to Improve Treatment of Chronic Kidney Disease

MELBOURNE, Australia - Dimerix Limited (ASX: DXB), a clinical stage biotechnology company is pleased to announce that it has partnered with a leader in predictive diagnostics, Proteomics International (ASX:PIQ), to improve the treatment of Chronic Kidney Disease (CKD).

Read more »

Seventure Partners’ Microbiome Portfolio is Reaching Critical Milestones in Current and Upcoming Clinical Trials

Paris, France – Seventure Partners, one of Europe’s leaders in financing innovation, and a world-leader in the venture investment in the microbiome sector, is seeing rapid progress from innovation into human trials, with five of its portfolio companies advancing their human microbiome products with varying modalities and therapeutics targets in clinical trials.

Read more »

Agendia: Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint® for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients

IRVINE, CA, AMSTERDAM, NETHERLANDS – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces findings of three studies presented at the 2017 San Antonio Breast Cancer Symposium (SABCS) last week.

Read more »

Forbion leads €25 million Series A fundraising in NorthSea Therapeutics and its promising NASH drug programme

Naarden, The Netherlands – Forbion Capital Partners (“Forbion”), one of the leading European life sciences venture capital firms investing in world-class healthcare technologies, today announced that NorthSea Therapeutics B.V. (‘NST’), a newly established Dutch biotech company, has completed a €25m Series A fundraising for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of non-alcoholic steatohepatitis (‘NASH’).

Read more »

NorthSea Therapeutics secures €25 million funding for clinical development of promising NASH drug

Naarden, The Netherlands – NorthSea Therapeutics B.V. (‘NST’), a newly established Dutch biotech company, announced today the completion of a €25m Series A funding for the development of icosabutate, a structurally engineered fatty acid (‘SEFA’) as a novel, oral approach for the treatment of non-alcoholic steatohepatitis (‘NASH’).

Read more »

Abzena Half year results: Growth strategy progressing

Cambridge, UK - Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2017.

Read more »

Abzena secures contract for integrated ADC manufacturing services to US biotech company

Cambridge, UK - Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (“ADC”) towards clinical trials.

Read more »

Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing

Vienna, Austria - Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that it has raised $59.6 million (€50.0 million) in an oversubscribed Series C financing.

Read more »

Uptick in M&A Activity and Investor Cash Expected to Re-invigorate Pharma and Biotech in 2018

London, Boston, Tokyo, San Francisco — The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong. According to EP Vantage, the editorial arm of Evaluate Ltd., the current business friendly stance at the FDA is unlikely to change next year, while M&A could see an uptick, driven by big pharma and big biotech’s need to re-stock pipelines and U.S. tax reforms.

Read more »

OCON Medical’s Hormone-Free Contraceptive Ballerine® Significantly Reduces Uterine Pain and Bleeding

Modiin, Israel  – OCON Medical (OCON), a pioneer in innovative women’s health products, today announces that its lead product IUB™ Ballerine® (Ballerine®) reduced bleeding and pain in a cohort of 366 women enrolled in a two-year follow-up trial. Ballerine® is a copper-based hormone-free contraceptive based on OCON’s proprietary IUB™ (intrauterine ball) platform.

Read more »

Expert Review Panel for Diagnostics Approves Atomo HIV Self Test for Procurement by Unitaid and the Global Fund

Sydney, Australia - Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources.

Read more »

Agendia and UZ Leuven Partner to Co-Validate MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch

Irvine, CA, USA, Amsterdam, Netherlands and Leuven, Belgium -- Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendia’s new in vitro diagnostic (IVD) MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit. The study is a key step in preparation for CE-marking and European launch of the kit in early 2018.

Read more »

Cell Medica announces appointment of industry leader Dr Annalisa Jenkins as Chair

London, UK and Houston, TX – Cell Medica (or ‘the Company’), a leader in next generation cellular immunotherapies for the treatment of cancer, today announced the appointment of Annalisa Jenkins, MBBS, FRCP, as Chair of the Board of Directors.

Read more »

Clinigen Plc: Directorate Change

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, announces that Chris Rigg has resigned with immediate effect as a director to seek a CEO role elsewhere.

Read more »

Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint® BluePrint® Breast Cancer Kit Co-Validation Study

Irvine, CA, Amsterdam, and Paris – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and Institute Curie in Paris, France, a leading player in the fight against cancer, announce a co-validation partnership for Agendia’s new in vitro diagnostic (IVD) MammaPrint® BluePrint® Breast Cancer Risk of Recurrence and Molecular Subtyping Kit.

Read more »

SmithsonHill to Deliver £500 Million Park to Revolutionise Growing AgriTech Sector Globally

Cambridge, UK – SmithsonHill, a joint venture between Russell Smith Farms and Hill Commercial Investment, is set to deliver one of the UK’s most significant AgriTech parks in South Cambridge. With a Gross Development Value exceeding half a billion pounds, the new park will offer more than 1 million square feet of lettable employment space and adjacent agricultural land to firms specialising in the AgriTech sector.

Read more »

Polyganics Awarded €1.2 million to Complete Clinical Development of Dura Sealant Patch

Groningen, The Netherlands – Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced it has been awarded funding from the European Fund for Regional Development (ERDF) by the European Union, to support clinical validation of its dura sealant patch. The grant, together with contributions from the city and province of Groningen, totals EUR 1.2 million. 

Read more »

SkinBioTherapeutics: Notification of First Patent Grant

Manchester, UK – SkinBioTherapeutics plc (AIM: SBTX,  the “Company”), a life science company focused on skin health, announces the granting of the first patent for its SkinBiotix® technology in Australia.

Read more »

New Data at the San Antonio Breast Cancer Symposium Demonstrate the Value of MammaPrint® and BluePrint® Across Breast Cancer Patient Populations

Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the presentation of extensive new data at the upcoming 2017 San Antonio Breast Cancer Symposium (SABCS), highlighting the value of its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test and BluePrint® Breast Cancer Molecular Subtyping Test. A total of eleven posters and discussions are being presented at SABCS, which will take place at the Henry B. Gonzales Convention Center in San Antonio, Texas from December 5-9, 2017.

Read more »

Trod Medical Granted New Patent for its Encage™ Prostate Focal Therapy Device

Leuven, Belgium – Trod Medical NV, a medical device company with FDA-cleared and CE Marked products for focal ablation, today announces it has been granted a new patent by the United States Patent and Trademark Office (USPTO) for its Encage™ Prostate Focal Therapy Device.

Read more »

Dimerix to Present at the 2nd World Congress for Clinical Trials in Diabetes

Melbourne, Australia - Dimerix Limited (ASX: DXB), a clinical stage biotechnology company announces that Associate Professor Dr David Packham has been invited to present both an oral and poster presentation at the 2nd World Congress for Clinical Trials in Diabetes between November 27-28 in Berlin, Germany.

Read more »

Agendia’s MammaPrint® Breast Cancer Risk-of-Recurrence Test Obtains Favorable Final Payment Determination from CMS for New, Unique Category 1 CPT Code

Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that its MammaPrint® 70-Gene Breast Cancer Risk-of-Recurrence Test has received a favorable payment determination for CY 2018 from the Centers for Medicare and Medicaid Services (CMS)1 for its new CPT code.

Read more »

Cristal Therapeutics Awarded €2.5 Million Horizon 2020 Grant to Advance Its CriPec®-docetaxel Through Phase 2 Trials

Maastricht, The Netherlands --  Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. The funds will be used to perform the upcoming Phase 2 trials of Cristal Therapeutics’ lead nanomedicine candidate CriPec®-docetaxel to evaluate efficacy and safety in specific solid tumour indications, and to generate supportive evidence for the beneficial bio-distribution profile.

Read more »

AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update

Irvine, CA, Amsterdam, Netherlands – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces that the American Joint Committee on Cancer (AJCC) has recently issued a Breast Cancer Update and Correction which revised and clarified the Cancer Staging Manual, 8th Edition regarding the use of multigene genomic profiles for Pathological Prognostic Staging.

Read more »

LiDia® BSI Test Demonstrates Rapid and Sensitive Identification of Bloodstream Infections Direct from Whole Blood Samples

London, UK and Carlsbad, CA, USA – DNAe, the inventor of semiconductor-based genomic analysis technologies, and the developer of a new, game-changing test for bloodstream infections that can lead to sepsis today announced new data on its test for bloodstream infections, LiDia® BSI. The data demonstrates the ability of the LiDia® BSI closed cartridge-based test to rapidly identify low levels of bacterial and fungal pathogens and resistance markers direct from whole blood, including an example of successful automation. The data were presented as a poster (ID31) at the Association for Molecular Pathology (AMP) Annual Meeting 2017 in Salt Lake City, UT, USA (16th – 18th November).

Read more »